We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.
- Authors
Uojima, Haruki; Yamasaki, Kazumi; Sugiyama, Masaya; Kage, Masayoshi; Ishii, Norihiro; Shirabe, Ken; Hidaka, Hisashi; Kusano, Chika; Murakawa, Miyako; Asahina, Yasuhiro; Nishimura, Takashi; Iijima, Hiroko; Sakamoto, Kazumasa; Ito, Kiyoaki; Amano, Keisuke; Kawaguchi, Takumi; Tamaki, Nobuharu; Kurosaki, Masayuki; Suzuki, Takanori; Matsuura, Kentaro
- Abstract
Background: The relationship between liver fibrosis and inflammation and Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with chronic liver disease (CLD) other than hepatitis C remains uncertain, owing to the limitations of qualitative methods. Here, we evaluated the influence of liver fibrosis and inflammation on quantitative M2BPGi (M2BPGi-Qt) in CLD, considering each etiology. Methods: We recruited 1373 patients with CLD. To evaluate the influence of liver fibrosis and inflammation on M2BPGi-Qt levels, we assessed M2BPGi-Qt levels at each fibrosis and activity stage within different etiologies of CLD based on pathological findings. Subsequently, we evaluated if the accuracy of fibrosis staging based on M2BPGi-Qt could be improved by considering the influence of liver inflammation. Results: In patients with viral hepatitis, non-alcoholic fatty liver disease, and primary biliary cholangitis, the median M2BPGi-Qt levels increased liver fibrosis progression. Median M2BPGi-Qt levels were not associated with the degree of fibrosis in patients with autoimmune hepatitis (AIH). Median M2BPGi-Qt levels increased with the progression of liver activity in all etiologies. A significant difference was found at each stage in AIH. Considering the liver inflammation, we established an algorithm, M2BPGi-Qt, to determine the alanine aminotransferase-to-platelet ratio (MAP-R) in liver cirrhosis (LC). The area under the receiver operating characteristic curve (AUC) of MAP-R was higher than that of the M2BPGi-Qt for detecting LC (AUC MAP-R = 0.759 and M2BPGi-Qt = 0.700, p < 0.001). Conclusions: The quantitative measurement system for M2BPGi depends on liver fibrosis and inflammation, regardless of etiology. Liver inflammation complicates the interpretation of M2BPGi-Qt results when assessing the fibrosis stage.
- Subjects
HEPATIC fibrosis; HEPATITIS; NON-alcoholic fatty liver disease; RECEIVER operating characteristic curves; VIRAL hepatitis
- Publication
Journal of Gastroenterology, 2024, Vol 59, Issue 7, p598
- ISSN
0944-1174
- Publication type
Article
- DOI
10.1007/s00535-024-02100-3